MedTrace Logo

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-01

No results posted yet for this study

Summary

A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.

Conditions

  • Candidemia

Interventions

DRUG

Interferon Gamma-1B

100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.

Sponsors & Collaborators

  • Horizon 2020 - European Commission

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Frank vd Veerdonk, Dr. · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2026-04-23
Completion
2026-04-23
FDA Drug
Yes

Countries

  • United States
  • Germany
  • Greece
  • Netherlands
  • Romania
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04979052 on ClinicalTrials.gov